UNSPSC 51322203: Rosuvastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C22H28FN3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 413KH5ZJ73, chemically known as (3r,5s,6e)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid but generally known as rosuvastatin, which bears US NIH Compound Identifier 446157. European Medicines Agency schedules Rosuvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20634.

UNSPSC 51322203 Rosuvastatin is a Commodity code under which state and local governments procure specific pharmaceutical products for emergency medical services, public health programs, and multistate cooperative purchasing networks. Recent solicitations show state and local buyers acquiring rosuvastatin and related cardiac and emergency medications through direct vendor contracts, cooperative purchasing agreements, and exploratory direct-to-manufacturer procurement initiatives. The issuing bodies include municipal fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions.

Activity appears concentrated in Florida and Minnesota, with Texas conducting early-stage market research into direct-manufacturer models. The City of Tampa Fire Rescue issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem, with an estimated contract value of $40,000, a one-year term, and a 5 percent SLBE bid discount; response deadline was April 8, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for Generic Multi Source Pharmaceuticals and OTC Products to be distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract performance through three authorized wholesalers beginning July 1, 2026. The Texas Health and Human Services Commission issued a Request for Information in March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling potential future formal solicitations but representing preliminary market intelligence gathering rather than current procurement activity.